drugset / Trial / NCT07197671
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
Phase 1
Recruiting
60 enrolled
University of Wisconsin, Madison
Archeus Technologies, Inc. · collabNational Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Participants with metastatic cancer who are taking anti-PD-1 or anti-PD-L1 therapy will be enrolled to assess the safety of and find the optimal dose for radioactive imaging agents and to explore whether these agents will make current drug therapies work better. Up to 60 participants will be enrolled and can expect to be on study for up to 9 months.
Timeline
- Start
- 2026-07-01
- Primary completion
- 2028-09
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 90Y-NM600 | Unknown | 740 mbq | — |
| Subject | 90Y-NM600 | Unknown | 1295 mbq | — |
| Subject | 90Y-NM600 | Unknown | 2590 mbq | — |
| Subject | 90Y-NM600 | Unknown | 3885 mbq | — |
| Subject | 90Y-NM600 | Unknown | 5180 mbq | — |